Rita Nahta, PhD
-
Research Program
-
Phone Number
-
Email Address
![Rita Nahta, PhD](_images/nahta-r-headshot.png)
Rita Nahta, PhD, is an assistant professor in the Department of Pharmacology and Chemical Biology at the Emory University School of Medicine. Dr. Nahta is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University.
Dr. Nahta received her PhD from Duke University in Durham, NC. She completed her postdoctoral fellow at Harvard Medical School in Cambridge, MA, and then M.D. Anderson Cancer Center in Houston, TX.
Dr. Nahta's laboratory focuses on the biological and therapeutic implications of growth factor signaling crosstalk in breast cancer. Significant advances in the treatment of metastatic breast cancer include the development of therapies targeted against specific cancer-causing molecules. However, the success of these mono-targeted therapies is often limited by cross-talk between multiple signaling pathways. One molecule that is overexpressed in about 25% of metastatic breast cancers is the HER2/erbB2 oncogene. Approved treatments for HER2-overexpressing breast cancer include the HER2-targeted antibody trastuzumab and the dual EGFR/HER2 kinase inhibitor lapatinib. While both drugs successfully treat a percentage of HER2-overexpressing metastatic breast cancers, a significant number of patients show primary or acquired resistance to these treatments.
Dr. Nahta's laboratory is interested in understanding how cross-talk between HER2 and other growth factor signaling pathways affects the biology of HER2-overexpressing breast cancers, including how signaling cross-talk promotes resistance to trastuzumab and lapatinib. By understanding the basic signaling mechanisms contributing to therapeutic resistance, they can identify new molecular targets against which future drugs can be developed.
Title/Journal | Authors | Publication Date |
---|---|---|
Using Online Cancer Genomics Databases to Provide Teaching Resources for Pharmacy Education. American journal of pharmaceutical education |
D Pasupuleti, T Nguyen, R Nahta | 11/01/2022 |
Biochemical pharmacology |
R Nahta, RC Castellino | 02/01/2021 |
Oncotarget |
BF Peake, SM Eze, L Yang, RC Castellino, R Nahta | 11/03/2020 |
Breast cancer research and treatment |
J Zhao, J Meisel, Y Guo, R Nahta, KL Hsieh, L Peng, Z Wei, R O'Regan, X Li | 10/01/2020 |
Clinical breast cancer |
JL Meisel, J Zhao, A Suo, C Zhang, Z Wei, C Taylor, R Aneja, U Krishnamurti, Z Li, R Nahta, R O'Regan, X Li | 02/01/2020 |
Neuro-oncology |
MP Akamandisa, K Nie, R Nahta, D Hambardzumyan, RC Castellino | 06/10/2019 |
Targeting forkhead box M1 transcription factor in breast cancer. Biochemical pharmacology |
RM O'Regan, R Nahta | 08/01/2018 |
ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. Expert opinion on biological therapy |
E Paplomata, R Nahta | 03/01/2018 |
Oncotarget |
BF Peake, SM Eze, L Yang, RC Castellino, R Nahta | 11/07/2017 |
Oncotarget |
L Qi, B Zhang, S Zhang, X Ci, Q Wu, G Ma, A Luo, L Fu, JL King, R Nahta, JT Dong | 05/30/2017 |
Oncogene |
J Wen, J Lee, A Malhotra, R Nahta, AR Arnold, MC Buss, BD Brown, C Maier, AM Kenney, M Remke, V Ramaswamy, MD Taylor, RC Castellino | 10/20/2016 |
PPM1D/WIP1 in medulloblastoma. Oncoscience |
MP Akamandisa, R Nahta, RC Castellino | 01/01/2016 |
Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in cancer biology |
KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, K Aquilano, J Arbiser, A Arreola, A Arzumanyan, SS Ashraf, AS Azmi, F Benencia, D Bhakta, A Bilsland, A Bishayee, SW Blain, PB Block, CS Boosani, TE Carey, A Carnero, M Carotenuto, SC Casey, M Chakrabarti, R Chaturvedi, GZ Chen, H Chen, S Chen, YC Chen, BK Choi, MR Ciriolo, HM Coley, AR Collins, M Connell, S Crawford, CS Curran, C Dabrosin, G Damia, S Dasgupta, RJ DeBerardinis, WK Decker, P Dhawan, AME Diehl, JT Dong, QP Dou, JE Drew, E Elkord, B El-Rayes, MA Feitelson, DW Felsher, LR Ferguson, C Fimognari, GL Firestone, C Frezza, H Fujii, MM Fuster, D Generali, AG Georgakilas, F Gieseler, M Gilbertson, MF Green, B Grue, G Guha, D Halicka, WG Helferich, P Heneberg, P Hentosh, MD Hirschey, LJ Hofseth, RF Holcombe, K Honoki, HY Hsu, GS Huang, LD Jensen, WG Jiang, LW Jones, PA Karpowicz, WN Keith, SP Kerkar, GN Khan, M Khatami, YH Ko, O Kucuk, RJ Kulathinal, NB Kumar, BS Kwon, A Le, MA Lea, HY Lee, T Lichtor, LT Lin, JW Locasale, BL Lokeshwar, VD Longo, CA Lyssiotis, KL MacKenzie, M Malhotra, M Marino, ML Martinez-Chantar, A Matheu, C Maxwell, E McDonnell, AK Meeker, M Mehrmohamadi, K Mehta, GA Michelotti, RM Mohammad, SI Mohammed, DJ Morre, V Muralidhar, I Muqbil, MP Murphy, GP Nagaraju, R Nahta, E Niccolai, S Nowsheen, C Panis, F Pantano, VR Parslow, G Pawelec, PL Pedersen, B Poore, D Poudyal, S Prakash, M Prince, L Raffaghello, JC Rathmell, WK Rathmell, SK Ray, J Reichrath, S Rezazadeh, D Ribatti, L Ricciardiello, RB Robey, F Rodier, HPV Rupasinghe, GL Russo, EP Ryan, AK Samadi, I Sanchez-Garcia, AJ Sanders, D Santini, M Sarkar, T Sasada, NK Saxena, RE Shackelford, HMC Shantha Kumara, D Sharma, DM Shin, D Sidransky, MD Siegelin, E Signori, N Singh, S Sivanand, D Sliva, C Smythe, C Spagnuolo, DM Stafforini, J Stagg, PR Subbarayan, T Sundin, WH Talib, SK Thompson, PT Tran, H Ungefroren, MG Vander Heiden, V Venkateswaran, DS Vinay, PJ Vlachostergios, Z Wang, KE Wellen, RL Whelan, ES Yang, H Yang, X Yang, P Yaswen, C Yedjou, X Yin, J Zhu, M Zollo | 12/01/2015 |
Seminars in cancer biology |
ARMR Amin, PA Karpowicz, TE Carey, J Arbiser, R Nahta, ZG Chen, JT Dong, O Kucuk, GN Khan, GS Huang, S Mi, HY Lee, J Reichrath, K Honoki, AG Georgakilas, A Amedei, A Amin, B Helferich, CS Boosani, MR Ciriolo, S Chen, SI Mohammed, AS Azmi, WN Keith, D Bhakta, D Halicka, E Niccolai, H Fujii, K Aquilano, SS Ashraf, S Nowsheen, X Yang, A Bilsland, DM Shin | 12/01/2015 |
Vaccines |
J Overholser, KH Ambegaokar, SM Eze, E Sanabria-Figueroa, R Nahta, T Bekaii-Saab, PT Kaumaya | 07/06/2015 |
Carcinogenesis |
WH Goodson, L Lowe, DO Carpenter, M Gilbertson, A Manaf Ali, A Lopez de Cerain Salsamendi, A Lasfar, A Carnero, A Azqueta, A Amedei, AK Charles, AR Collins, A Ward, AC Salzberg, A Colacci, AK Olsen, A Berg, BJ Barclay, BP Zhou, C Blanco-Aparicio, CJ Baglole, C Dong, C Mondello, CW Hsu, CC Naus, C Yedjou, CS Curran, DW Laird, DC Koch, DJ Carlin, DW Felsher, D Roy, DG Brown, E Ratovitski, EP Ryan, E Corsini, E Rojas, EY Moon, E Laconi, F Marongiu, F Al-Mulla, F Chiaradonna, F Darroudi, FL Martin, FJ Van Schooten, GS Goldberg, G Wagemaker, GN Nangami, GM Calaf, G Williams, GT Wolf, G Koppen, G Brunborg, HK Lyerly, H Krishnan, H Ab Hamid, H Yasaei, H Sone, H Kondoh, HK Salem, HY Hsu, HH Park, I Koturbash, IR Miousse, AI Scovassi, JE Klaunig, J Vondráček, J Raju, J Roman, JP Wise, JR Whitfield, J Woodrick, JA Christopher, J Ochieng, JF Martinez-Leal, J Weisz, J Kravchenko, J Sun, KR Prudhomme, KB Narayanan, KA Cohen-Solal, K Moorwood, L Gonzalez, L Soucek, L Jian, LS D'Abronzo, LT Lin, L Li, L Gulliver, LJ McCawley, L Memeo, L Vermeulen, L Leyns, L Zhang, M Valverde, M Khatami, MF Romano, M Chapellier, MA Williams, M Wade, MH Manjili, ME Lleonart, M Xia, MJ Gonzalez, MV Karamouzis, M Kirsch-Volders, M Vaccari, NB Kuemmerle, N Singh, N Cruickshanks, N Kleinstreuer, N van Larebeke, N Ahmed, O Ogunkua, PK Krishnakumar, P Vadgama, PA Marignani, PM Ghosh, P Ostrosky-Wegman, PA Thompson, P Dent, P Heneberg, P Darbre, P Sing Leung, P Nangia-Makker, QS Cheng, RB Robey, R Al-Temaimi, R Roy, R Andrade-Vieira, RK Sinha, R Mehta, R Vento, R Di Fiore, R Ponce-Cusi, R Dornetshuber-Fleiss, R Nahta, RC Castellino, R Palorini, R Abd Hamid, SA Langie, SE Eltom, SA Brooks, S Ryeom, SS Wise, SN Bay, SA Harris, S Papagerakis, S Romano, S Pavanello, S Eriksson, S Forte, SC Casey, S Luanpitpong, TJ Lee, T Otsuki, T Chen, T Massfelder, T Sanderson, T Guarnieri, T Hultman, V Dormoy, V Odero-Marah, V Sabbisetti, V Maguer-Satta, WK Rathmell, W Engström, WK Decker, WH Bisson, Y Rojanasakul, Y Luqmani, Z Chen, Z Hu | 06/01/2015 |
Carcinogenesis |
R Nahta, F Al-Mulla, R Al-Temaimi, A Amedei, R Andrade-Vieira, SN Bay, DG Brown, GM Calaf, RC Castellino, KA Cohen-Solal, A Colacci, N Cruickshanks, P Dent, R Di Fiore, S Forte, GS Goldberg, RA Hamid, H Krishnan, DW Laird, A Lasfar, PA Marignani, L Memeo, C Mondello, CC Naus, R Ponce-Cusi, J Raju, D Roy, R Roy, EP Ryan, HK Salem, AI Scovassi, N Singh, M Vaccari, R Vento, J Vondráček, M Wade, J Woodrick, WH Bisson | 06/01/2015 |
Oncotarget |
L Taliaferro-Smith, E Oberlick, T Liu, T McGlothen, T Alcaide, R Tobin, S Donnelly, R Commander, E Kline, GP Nagaraju, L Havel, A Marcus, R Nahta, R O'Regan | 03/10/2015 |
Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach? Cancer |
E Paplomata, R Nahta, RM O'Regan | 02/15/2015 |
Molecular pharmacology |
E Sanabria-Figueroa, SM Donnelly, KC Foy, MC Buss, RC Castellino, E Paplomata, L Taliaferro-Smith, PT Kaumaya, R Nahta | 02/01/2015 |
Oncoimmunology |
MJ Miller, KC Foy, JP Overholser, R Nahta, PT Kaumaya | 11/01/2014 |
Oncoimmunology |
KC Foy, MJ Miller, J Overholser, SM Donnelly, R Nahta, PT Kaumaya | 11/01/2014 |
Resistance to HER2-targeted therapies: a potential role for FOXM1. Breast cancer management |
BF Peake, R Nahta | 01/01/2014 |
P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer. Current medicinal chemistry |
SM Donnelly, E Paplomata, BM Peake, E Sanabria, Z Chen, R Nahta | 01/01/2014 |
Human epidermal growth factor receptor 2-targeted therapies in breast cancer. Expert opinion on biological therapy |
R Nahta | 07/01/2013 |
Current pharmacogenomics and personalized medicine |
SE Griner, KJ Wang, JP Joshi, R Nahta | 03/01/2013 |
Biochemical pharmacology |
SE Griner, JP Joshi, R Nahta | 01/01/2013 |
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. Current medicinal chemistry |
SS Gayle, RC Castellino, MC Buss, R Nahta | 01/01/2013 |
Catalytic deoxyribozyme-modified nanoparticles for RNAi-independent gene regulation. ACS nano |
K Yehl, JP Joshi, BL Greene, RB Dyer, R Nahta, K Salaita | 10/23/2012 |
Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast cancer research and treatment |
R Nahta, RM O'Regan | 08/01/2012 |
New developments in the treatment of HER2-positive breast cancer. Breast cancer (Dove Medical Press) |
R Nahta | 05/01/2012 |
Anti-cancer agents in medicinal chemistry |
SS Gayle, SL Arnold, RM O'Regan, R Nahta | 02/01/2012 |
Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemotherapy research and practice |
R Nahta | 01/01/2012 |
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Current medicinal chemistry |
R Nahta | 01/01/2012 |
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN oncology |
R Nahta | 01/01/2012 |
Biochemical pharmacology |
JP Joshi, NE Brown, SE Griner, R Nahta | 11/01/2011 |
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines. Current pharmacogenomics and personalized medicine |
A Crawford, R Nahta | 09/01/2011 |
Clinical breast cancer |
R Nahta, RM O'Regan | 11/01/2010 |
Cancer chemotherapy and pharmacology |
T Ozbay, DL Durden, T Liu, RM O'Regan, R Nahta | 03/01/2010 |
Current pharmacogenomics and personalized medicine |
R Nahta, S Shabaya, T Ozbay, DL Rowe | 12/01/2009 |
Breast cancer : basic and clinical research |
DL Rowe, T Ozbay, RM O'Regan, R Nahta | 09/02/2009 |
Molecular cancer therapeutics |
DL Rowe, T Ozbay, LM Bender, R Nahta | 07/01/2008 |
Molecular cancer research : MCR |
T Ozbay, R Nahta | 06/01/2008 |
Her2 cross talk and therapeutic resistance in breast cancer. Frontiers in bioscience : a journal and virtual library |
LM Bender, R Nahta | 05/01/2008 |